| Source: |
| Type: |
| Drug dosage vs efficacy, and actual dosage number of research papers. |
| 2511- | H2, | Molecular hydrogen suppresses glioblastoma growth via inducing the glioma stem-like cell differentiation |
| - | in-vivo, | GBM, | U87MG |
| 2524- | H2, | Protective effect of hydrogen-rich water on liver function of colorectal cancer patients treated with mFOLFOX6 chemotherapy |
| - | Trial, | NA, | NA |
| 2513- | H2, | Hydrogen therapy: from mechanism to cerebral diseases |
| - | Review, | Stroke, | NA |
| 2512- | H2, | Hydrogen Attenuates Allergic Inflammation by Reversing Energy Metabolic Pathway Switch |
| - | in-vivo, | asthmatic, | NA |
| 2509- | H2, | Hydrogen inhibits endometrial cancer growth via a ROS/NLRP3/caspase-1/GSDMD-mediated pyroptotic pathway |
| - | in-vitro, | Endo, | AN3CA | - | in-vivo, | Endo, | NA |
| 2506- | H2, | Molecular hydrogen suppresses activated Wnt/β-catenin signaling |
| - | in-vivo, | Arthritis, | NA |
| 2505- | H2, | Hydrogen gas restores exhausted CD8+ T cells in patients with advanced colorectal cancer to improve prognosis |
| - | Trial, | CRC, | NA |
| 2504- | H2, | Hydrogen gas activates coenzyme Q10 to restore exhausted CD8+ T cells, especially PD-1+Tim3+terminal CD8+ T cells, leading to better nivolumab outcomes in patients with lung cancer |
| - | Trial, | Lung, | NA |
| 2503- | H2, | Brain Metastases Completely Disappear in Non-Small Cell Lung Cancer Using Hydrogen Gas Inhalation: A Case Report |
| - | Case Report, | Lung, | NA |
| 2527- | H2, | The healing effect of hydrogen-rich water on acute radiation-induced skin injury in rats |
| - | in-vivo, | Wounds, | NA |
| 2530- | H2, | Improvement of psoriasis-associated arthritis and skin lesions by treatment with molecular hydrogen: A report of three cases |
| - | Case Report, | PSA, | NA |
| 3152- | H2, | VitC, | Rad, | Hydrogen and Vitamin C Combination Therapy: A Novel Method of Radioprotection |
| - | in-vitro, | Nor, | HUVECs | - | in-vivo, | NA, | NA |
| 4307- | H2, | Hydrogen Gas Attenuates Toxic Metabolites and Oxidative Stress-Mediated Signaling to Inhibit Neurodegeneration and Enhance Memory in Alzheimer’s Disease Models |
| - | in-vivo, | AD, | NA |
| 4308- | H2, | A biomimetic upconversion nanoreactors for near-infrared driven H2 release to inhibit tauopathy in Alzheimer's disease therapy |
| - | in-vivo, | AD, | NA |
| 1631- | HCA, | An overview of the safety and efficacy of a novel, natural(-)-hydroxycitric acid extract (HCA-SX) for weight management |
| - | Review, | Obesity, | NA |
| 1645- | HCAs, | Chapter 8 - Hydroxycinnamic Acids: Natural Sources, Biosynthesis, Possible Biological Activities, and Roles in Islamic Medicine |
| - | Review, | Nor, | NA |
| 1641- | HCAs, | Lung cancer induced by Benzo(A)Pyrene: ChemoProtective effect of sinapic acid in swiss albino mice |
| - | in-vitro, | Lung, | A549 | - | in-vivo, | Lung, | NA |
| 1643- | HCAs, | Mechanisms involved in the anticancer effects of sinapic acid |
| - | Review, | Var, | NA |
| 1644- | HCAs, | PBG, | Artepillin C (3,5-diprenyl-4-hydroxycinnamic acid) sensitizes LNCaP prostate cancer cells to TRAIL-induced apoptosis |
| - | in-vitro, | Pca, | LNCaP |
| 2079- | HNK, | Honokiol Microemulsion Causes Stage-Dependent Toxicity Via Dual Roles in Oxidation-Reduction and Apoptosis through FoxO Signaling Pathway |
| - | in-vitro, | Nor, | PC12 |
| 2873- | HNK, | Honokiol Alleviates Oxidative Stress-Induced Neurotoxicity via Activation of Nrf2 |
| - | in-vitro, | Nor, | PC12 |
| 2864- | HNK, | Honokiol: A Review of Its Anticancer Potential and Mechanisms |
| - | Review, | Var, | NA |
| 3803- | Hup, | Huperzine A and Its Neuroprotective Molecular Signaling in Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 2180- | itraC, | Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent |
| - | Review, | Var, | NA |
| 1917- | JG, | Inhibition of human leukemia cells growth by juglone is mediated via autophagy induction, endogenous ROS production, and inhibition of cell migration and invasion |
| - | in-vitro, | AML, | HL-60 |
| 4011- | K+, | Sodium and potassium intakes among US adults: NHANES 2003–2008 |
| - | Analysis, | NA, | NA |
| 4005- | K+, | Potassium |
| - | Review, | Nor, | NA | - | Review, | Stroke, | NA |
| - | in-vitro, | Nor, | MCF10 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | PC, | Bxpc-3 |
| 2906- | LT, | Luteolin, a flavonoid with potentials for cancer prevention and therapy |
| - | Review, | Var, | NA |
| 3268- | Lyco, | Lycopene as a Natural Antioxidant Used to Prevent Human Health Disorders |
| - | Review, | AD, | NA |
| 3277- | Lyco, | Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent |
| - | Review, | Var, | NA |
| 1713- | Lyco, | Lycopene: A Potent Antioxidant with Multiple Health Benefits |
| - | Review, | Nor, | NA |
| 1711- | Lyco, | Nutritional Importance of Carotenoids and Their Effect on Liver Health: A Review |
| - | Review, | Var, | NA |
| 1716- | Lyco, | Anti-inflammatory Activity of β-Carotene, Lycopene and Tri-n-butylborane, a Scavenger of Reactive Oxygen Species |
| - | in-vitro, | AML, | RAW264.7 |
| 4784- | Lyco, | Protective effects of lycopene in cancer, cardiovascular, and neurodegenerative diseases: An update on epidemiological and mechanistic perspectives |
| - | Review, | Diabetic, | NA | - | Review, | CardioV, | NA |
| 4788- | Lyco, | Lycopene as a potential anticancer agent: Current evidence on synergism, drug delivery systems and epidemiology (Review) |
| - | Review, | Var, | NA |
| 2644- | MCT, | The Effects of Medium-Chain Triglyceride Oil Supplementation on Endurance Performance and Substrate Utilization in Healthy Populations: A Systematic Review |
| - | Review, | Nor, | NA |
| 1776- | MEL, | Therapeutic strategies of melatonin in cancer patients: a systematic review and meta-analysis |
| - | Review, | NA, | NA |
| 1783- | MEL, | The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials |
| - | Review, | Var, | NA |
| 1782- | MEL, | Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities |
| - | Review, | Var, | NA |
| 1779- | MEL, | Therapeutic Potential of Melatonin Counteracting Chemotherapy-Induced Toxicity in Breast Cancer Patients: A Systematic Review |
| - | Review, | BC, | NA |
| 1778- | MEL, | Melatonin: a well-documented antioxidant with conditional pro-oxidant actions |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 5804- | MET, | NIV, | Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up. |
| - | Case Report, | PC, | NA |
| 2385- | MET, | Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model |
| - | in-vitro, | AD, | H4 | - | in-vitro, | NA, | HEK293 | - | in-vivo, | NA, | NA | - | in-vitro, | NA, | SH-SY5Y |
| 2489- | metroC, | capec, | Long-lasting response with metronomic capecitabine in advanced hepatocellular carcinoma |
| - | Case Report, | HCC, | NA |
| 2488- | metroC, | Metronomic S-1 Chemotherapy and Vandetanib: An Efficacious and Nontoxic Treatment for Hepatocellular Carcinoma |
| - | in-vitro, | HCC, | HUH7 | - | in-vivo, | HCC, | NA |
| 2486- | metroC, | capec, | Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases |
| - | Case Report, | HCC, | NA |
| 2250- | MF, | MNPs, | Confronting stem cells with surface-modified magnetic nanoparticles and low-frequency pulsed electromagnetic field |
| - | Review, | NA, | NA |
| 1762- | MF, | Fe, | Triggering the apoptosis of targeted human renal cancer cells by the vibration of anisotropic magnetic particles attached to the cell membrane |
| - | in-vitro, | RCC, | NA |
| 4102- | MF, | Modulation of antioxidant enzyme gene expression by extremely low frequency electromagnetic field in post-stroke patients |
| - | Human, | Stroke, | NA |
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1114 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid